We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Methods Compared for Quantitative Detection of Epstein-Barr Virus

By LabMedica International staff writers
Posted on 31 May 2016
Print article
Image: A scanning electron micrograph (SEM) of budding Epstein-Barr virus and a B-cell lymphocyte (Photo courtesy of the Albert Einstein College of Medicine).
Image: A scanning electron micrograph (SEM) of budding Epstein-Barr virus and a B-cell lymphocyte (Photo courtesy of the Albert Einstein College of Medicine).
Quantitative detection of Epstein-Barr virus by real time polymerase chain reaction (PCR) has become standard of care in the management of immunocompromised patients and is integral to their treatment.

The performance characteristics of four real-time assays, three that use different analyte specific reagent (ASRs) and one that uses laboratory-developed reagents, have been compared with one another for the detection of Epstein-Barr virus (EBV) in whole blood.

Scientists at St. Jude Children's Research Hospital (Memphis, TN, USA) seeded whole blood specimens with EBV, which were used to determine quantitative linearity, analytical measurement range, lower limit of detection, and coefficient of variation (CV) for each assay. Retrospective testing of 198 clinical samples was performed in parallel with all methods; results were compared to determine relative quantitative and qualitative performance.

The ASRs used in the study were produced by Focus Diagnostics (Cypress, CA, USA), Luminex Corporation (Austin, TX, USA), and ELITechGroup (Bothell, WA, USA). The modified laboratory diagnostic test (LDT) was used with the QX100 ddPCR system (Bio-Rad, Hercules, CA, USA) for droplet digital (ddPCR) amplification.

The investigators found that all the assays showed similar performance with no significant difference was found in limit of detection (3.12–3.49 log10 copies/mL). A strong qualitative correlation was seen with all assays that used clinical samples with positive detection rates of 89.5% to 95.8%. Quantitative correlation of clinical samples across assays was also seen in pairwise regression analysis. Normalizing clinical sample results to IU/mL did not alter the quantitative correlation between assays.

The team notes that the Focus ASR reagents can be stored at 4 °C after the first thaw, saving time for future test preparation. The latter assay runs on a 96-well disk in a small volume, and the PCR can be performed in less than an hour, using the 3M Integrated Cycler. However, great attention is needed to load the disk. The other three methods use 96-well plates, and the PCRs were run on an Applied Biosystem sequence detection system 7500, but it could be run on other systems that accept 96-well plates.

The authors concluded that quantitative EBV detection by real-time PCR can be performed over a wide linear dynamic range, using three different commercially available reagents and laboratory-developed methods. EBV was detected with comparable sensitivity and quantitative correlation for all assays. The study was published online on May 22, 2016, in the Journal of Molecular Diagnostics.

Related Links:
St. Jude Children's Research Hospital
Focus Diagnostics
Luminex
ELITechGroup
Bio-Rad
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.